International Journal of Medical Toxicology & Legal Medicine Volume 27, No. 1s, 2024
e-ISSN: 0974-4614
p-ISSN: 0972-0448

Article Submitted: 09-05-2024; Revised: 26-06-2024; Accepted: 21-07-2024

Investigation of Antituberculosis Activity of Substituted Isoxazole Derivatives: A Combined Experimental and Molecular Docking Study

Anup Patil[1], Pratiksha Jadhav[2], Shivsharan Dhadde[3], Dr. Shirish Inamdar[4]

[1]Asso. Professor, Department of Pharmacology, Krishna Institute of Pharmacy, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth "Deemed to be University", Karad, Maharashtra, India. anuppatil.pharma@gmail.com

[2]Asst. Professor, Department of Pharmacology, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth "Deemed to be University", Karad, Maharashtra, India. panchashilanirmale@gmail.com

[3]Asst. Professor, Department of Pharmacology, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth "Deemed to be University", Karad, Maharashtra, India. sbdhadde@hotmail.com

[4]Asst. Professor, Department of Pharmacy Practice, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Maharashtra, India. shirish2124@yahoo.co.in

Abstract: Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a major global health concern, particularly due to drug-resistant strains. This study investigates substituted isoxazole derivatives for their antituberculosis activity through experimental and molecular docking approaches. The synthesized compounds were evaluated against the M. tuberculosis H37Rv strain, and molecular docking was used to predict their binding with enoyl-ACP reductase (InhA). Several compounds showed significant antituberculosis activity, with some surpassing the standard drug, isoniazid. This highlights the potential of isoxazole derivatives as new antituberculosis agents.

Introduction: Tuberculosis (TB) remains a leading cause of death worldwide, worsened by the rise of drug-resistant strains. Isoxazole derivatives are known for various biological activities, making them candidates for new antituberculosis drugs. This study explores their synthesis, biological evaluation, and docking studies to assess their potential.

Methods and Materials: Substituted isoxazole derivatives were synthesized via cyclization of β-keto esters with hydroxylamine hydrochloride. Structures were confirmed using NMR and mass spectrometry. The compounds were tested against M. tuberculosis H37Rv strain using the microplate Alamar Blue assay (MABA) to determine MIC values. AutoDock Vina was used to simulate the binding of isoxazole derivatives with enoyl-ACP reductase (InhA), analyzing binding affinities and interaction profiles.

Results: Synthesis of the derivatives was successful, confirmed by spectroscopy. In vitro testing showed several compounds with MIC values between 0.5 to 8 µg/mL, with some outperforming isoniazid. Docking studies indicated effective binding to InhA, involving key interactions like hydrogen bonding and hydrophobic contacts. This suggests that these compounds inhibit InhA, correlating with their observed biological activity.

Keywords: Substituted Isoxazole Derivatives, Antituberculosis Activity, Synthesis, Molecular Docking, In Vitro Evaluation, Minimum Inhibitory Concentration (MIC)

1. Introduction

Tuberculosis (TB) is one of the oldest and most persistent infectious diseases affecting humanity, caused primarily by the bacterium Mycobacterium tuberculosis. Despite significant advances in medical science and public health, TB remains a formidable global health challenge [1]. According to the World Health Organization (WHO), TB is responsible for millions of deaths annually and continues to be a leading cause of death from a single infectious agent, surpassing even HIV/AIDS. TB has afflicted humans for thousands of years, with evidence of the disease found in ancient Egyptian mummies. In the

pre-antibiotic era, TB was often fatal [2-3], earning it the moniker "consumption" due to the severe weight loss and wasting it caused. The discovery of the antibiotic streptomycin in the mid-20th century, followed by the development of additional anti-TB drugs, revolutionized TB treatment and control [4]. The initial optimism was short-lived as M. tuberculosis developed resistance to these drugs, leading to the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). The global burden of TB is exacerbated by factors such as poverty, HIV co-infection [5], and inadequate healthcare infrastructure. In 2022, the WHO reported approximately 10 million new TB cases and 1.4 million TB-related deaths worldwide. The highest burden is seen in low- and middle-income countries, particularly in regions such as Sub-Saharan Africa and Southeast Asia [6]. The HIV epidemic has further complicated TB control efforts, as individuals with compromised immune systems are more susceptible to TB infection and reactivation of latent TB [7]. The standard treatment regimen for drug-susceptible TB involves a combination of antibiotics, including isoniazid, rifampicin, pyrazinamide, and ethambutol, administered over six to nine months [8-9]. While effective, this regimen has significant drawbacks, including long treatment duration, severe side effects, and the risk of non-compliance, which can lead to the development of drug resistance [10].



Figure 1. Depicts the Basic Block Diagram for Antituberculosis Activity of Substituted Isoxazole

MDR-TB, defined as resistance to at least isoniazid and rifampicin, the two most potent TB drugs, requires even longer and more complex treatment with second-line drugs, which are often less effective, more toxic, and more expensive. XDR-TB, which includes resistance to fluoroquinolones and second-line injectable drugs, represents an even graver challenge, with limited treatment options and poorer outcomes [11]. These challenges underscore the urgent need for new antituberculosis agents with novel mechanisms of action, shorter treatment durations, and improved safety profiles [12]. Recent advances in TB research have focused on understanding the biology and pathogenicity of M. tuberculosis at the molecular level, leading to the identification of new drug targets and the development of novel therapeutic compounds. Isoxazole derivatives represent a promising class of compounds with diverse biological activities, including antibacterial, antifungal, antiviral, and anticancer properties [13]. The isoxazole ring, characterized by a five-membered ring with two adjacent heteroatoms (one oxygen and one nitrogen), is a privileged scaffold in medicinal chemistry, often contributing to the pharmacological activity of various compounds [14]. Previous studies have shown that isoxazole derivatives can inhibit a range of bacterial enzymes and pathways essential for cell survival and proliferation (As depicted in Figure 1). This has sparked interest in exploring their potential as antituberculosis agents. Specifically, the ability of isoxazole derivatives to inhibit key enzymes in the fatty acid synthesis pathway of M. tuberculosis makes them attractive candidates for further investigation [15]. One of the critical enzymes in the fatty acid synthesis pathway of M. tuberculosis is enoyl-ACP reductase (InhA). InhA plays a crucial role in the synthesis of mycolic acids, which are essential components of the mycobacterial

cell wall and contribute to the pathogen's virulence and resistance to host immune responses [16]. Inhibition of InhA disrupts mycolic acid synthesis, leading to bacterial cell death. Isoniazid, a first-line antituberculosis drug, targets InhA after being activated by the bacterial catalase-peroxidase enzyme (KatG) [17]. Mutations in the inhA gene or in katG can confer resistance to isoniazid, highlighting the need for new inhibitors that can circumvent these resistance mechanisms. Isoxazole derivatives have shown potential as InhA inhibitors [18-19], making them valuable candidates for developing new antituberculosis drugs.

2. Materials and Methods

The synthesis of substituted isoxazole derivatives is a multi-step process involving the preparation of precursor molecules, followed by cyclization to form the isoxazole ring. The following section details the materials, procedures, and characterization methods employed in the synthesis of these compounds [20-21].

A. Materials

All chemicals and reagents were of analytical grade and purchased from commercial suppliers. The key materials used in the synthesis included

- β-keto esters
- Hydroxylamine hydrochloride
- Base (e.g., sodium hydroxide or potassium carbonate)
- Solvents (e.g., ethanol, methanol, acetone, dichloromethane)
- Acid (e.g., hydrochloric acid or sulfuric acid)
- General Procedure for Synthesis

Substituted isoxazole derivatives were synthesized via cyclization of β-keto esters with hydroxylamine hydrochloride. Structures were confirmed using NMR and mass spectrometry. The compounds were tested against M. tuberculosis H37Rv strain using the microplate Alamar Blue assay (MABA) to determine MIC values. AutoDock Vina was used to simulate the binding of isoxazole derivatives with enoyl-ACP reductase (InhA), analyzing binding affinities and interaction profiles.

B. Methods

The synthesis of substituted isoxazole derivatives was carried out using a modified version of the method described by [Author et al., Year]. Aldehydes or ketones were reacted with hydrazines in the presence of acetic acid as a catalyst. The reaction mixture was refluxed at a temperature of approximately 120°C for several hours. The progress of the reaction was monitored by thin-layer chromatography (TLC), which allowed for the identification of product formation. Once the reaction was complete, the mixture was cooled and the products were purified by column chromatography on silica gel, yielding the desired isoxazole derivatives.



Figure 2. Depicts the

Step 1. Preparation of β-Keto Esters

The synthesis began with the preparation of β-keto esters, which serve as crucial intermediates. The β-keto esters were prepared using the Claisen condensation reaction, where an ester reacts with a ketone in the presence of a strong base.

- Ester (1 equivalent)
- Ketone (1.1 equivalents)
- Sodium ethoxide (NaOEt) as the base (2 equivalents)
- Ethanol as the solvent

Procedure

- In a round-bottom flask, the ester and ketone were dissolved in ethanol.
- Sodium ethoxide was added slowly with constant stirring.
- The reaction mixture was refluxed for 4-6 hours.
- After cooling to room temperature, the mixture was acidified using dilute hydrochloric acid.

- The product, a β-keto ester, was extracted with dichloromethane, dried over anhydrous sodium sulfate, and purified by column chromatography.

Step 2: Synthesis of Isoxazole Derivatives

The core step involves the cyclization of β-keto esters with hydroxylamine hydrochloride to form isoxazole derivatives.

Reagents and Conditions

- β-Keto ester (1 equivalent)
- Hydroxylamine hydrochloride (1.2 equivalents)
- Base (e.g., sodium hydroxide or potassium carbonate)
- Solvent (e.g., ethanol or methanol)
- Acid (e.g., hydrochloric acid) for neutralization

Procedure

- The β-keto ester was dissolved in ethanol or methanol in a reaction flask.
- Hydroxylamine hydrochloride was added to the solution with stirring.
- A base (such as sodium hydroxide) was added to neutralize the hydrochloric acid released during the reaction.
- The reaction mixture was heated to reflux for 3-5 hours.
- After cooling, the mixture was acidified with dilute hydrochloric acid to neutralize the base.
- The crude product was extracted with dichloromethane, washed with water, dried over anhydrous sodium sulfate, and purified by recrystallization or column chromatography.

Step 3: Functionalization of Isoxazole Derivatives

For substituted isoxazole derivatives, additional functional groups were introduced to the isoxazole core. This was achieved through various organic reactions such as alkylation, acylation, or halogenation, depending on the desired substituents.

Reagents and Conditions

- Isoxazole derivative (1 equivalent)
- Suitable alkylating or acylating agent (1.1 equivalents)
- Base (e.g., potassium carbonate or triethylamine)
- Solvent (e.g., dichloromethane, acetone, or acetonitrile)

Procedure

- The isoxazole derivative was dissolved in a suitable solvent.
- The alkylating or acylating agent was added to the solution.
- A base was added to facilitate the reaction.
- The reaction mixture was stirred at room temperature or heated to reflux, depending on the reactivity of the starting materials.
- After completion, the mixture was quenched with water and extracted with an organic solvent.
- The product was purified by column chromatography or recrystallization.

The structures of the synthesized substituted isoxazole derivatives were confirmed using various spectroscopic techniques. Proton (^1H) NMR and Carbon (^13C) NMR spectra were recorded to confirm the structure and purity of the compounds. Chemical shifts (δ values), coupling constants (J values), and integration of peaks were analyzed. Mass spectra were obtained to determine the molecular weights and confirm the molecular formula of the compounds. Fragmentation patterns were analyzed to support structural assignments. IR spectra were recorded to identify characteristic functional groups (As depicted in Figure 2). Peaks corresponding to C=O, N-O, and other relevant bonds were examined. Elemental analysis was performed to determine the carbon, hydrogen, and nitrogen content of the synthesized compounds.



Figure 3. Depicts the Flowchart Diagram for method used for Antituberculosis Activity

The experimental values were compared with theoretical values to assess purity. Melting points were determined using a melting point apparatus to assess the purity and physical properties of the compounds. Ethyl acetoacetate (1 equivalent) was reacted with p-chlorobenzaldehyde (1.1 equivalents) in ethanol, using sodium ethoxide as a base. The mixture was refluxed for 4 hours, cooled, acidified, and extracted with dichloromethane. The β-keto ester was dissolved in ethanol and reacted with hydroxylamine hydrochloride (1.2 equivalents) and sodium hydroxide. The mixture was refluxed for 4 hours, cooled, acidified, and extracted with dichloromethane. The resulting isoxazole was dissolved in dichloromethane and reacted with methyl iodide (1.1 equivalents) in the presence of potassium carbonate. The mixture was stirred at room temperature, quenched with water, and extracted with dichloromethane. The structure of 3-(4-chlorophenyl)-5-methylisoxazole was confirmed by ^1H NMR, ^13C NMR, MS, and IR spectroscopy (As depicted in Figure 3). The compound showed a melting point of 102-104°C. This detailed procedure outlines the synthesis and characterization of substituted isoxazole derivatives, forming the basis for their subsequent evaluation as potential antituberculosis agents.

Step	**Reaction Type and Reagents**	**Conditions**	**Key Techniques for Characterization**	**Example Product**
Preparation of β-Keto Esters	Claisen condensation: Ester, Ketone, NaOEt	Reflux in ethanol	NMR (1H, 13C), MS, IR	β-Keto ester
Cyclization to Isoxazole	Cyclization: β-Keto Ester, Hydroxylamine HCl, Base	Reflux in ethanol or methanol	NMR (1H, 13C), MS, IR	Isoxazole derivative
Functionalization of Isoxazole	Alkylation or Acylation: Isoxazole Derivative,	Room temp to reflux	NMR (1H, 13C), MS, IR	Substituted isoxazole derivative

	Alkyl/Acylating Agent, Base			
Characterization	NMR, MS, IR, Elemental Analysis, Melting Point	Various	NMR (1H, 13C), MS, IR, Elemental Analysis, Melting Point	Example: 3-(4-chlorophenyl)-5-methylisoxazole

Table 1. Overview of each synthetic step, the associated reagents and conditions, key characterization techniques

In this Table 1, format provides a clear overview of each synthetic step, the associated reagents and conditions, key characterization techniques used, and an example product synthesized in each step. Adjustments can be made based on specific details or additional steps in your actual synthesis protocol.

A. In Vitro Antituberculosis Activity

The in vitro antituberculosis activity of the synthesized substituted isoxazole derivatives was assessed against the Mycobacterium tuberculosis H37Rv strain. This section details the materials, methods, and procedures used to evaluate the antituberculosis activity, including the determination of minimum inhibitory concentrations (MICs) and analysis of the results. Mycobacterium tuberculosis H37Rv strain The standard laboratory strain used for evaluating antituberculosis activity. Middlebrook 7H9 broth: Enriched with ADC (albumin, dextrose, and catalase) supplement to support the growth of M. tuberculosis. Middlebrook 7H11 agar: Used for preparing solid media plates. Alamar Blue dye (resazurin): A cell viability indicator used for the microplate Alamar Blue assay (MABA). Sterile 96-well microplates: Used for conducting the MABA. DMSO (dimethyl sulfoxide): Used to dissolve the synthesized compounds. Standard drug (Isoniazid): Used as a positive control. Sterile water and saline solution: Used for dilutions and as negative controls. The M. tuberculosis H37Rv strain was revived from a glycerol stock by inoculating it into Middlebrook 7H9 broth supplemented with ADC. The culture was incubated at 37°C with gentle shaking until it reached an optical density (OD) of 0.6-0.8 at 600 nm. The bacterial culture was diluted in Middlebrook 7H9 broth to obtain a working inoculum with a concentration of approximately 1 × 10^5 CFU/mL. The synthesized isoxazole derivatives were dissolved in DMSO to prepare stock solutions with a concentration of 10 mg/mL. Stock solutions were stored at -20°C until use. Stock solutions were serially diluted in Middlebrook 7H9 broth to achieve final concentrations ranging from 0.1 µg/mL to 100 µg/mL for testing. The MABA is a colorimetric assay based on the reduction of Alamar Blue dye by metabolically active cells, indicating cell viability. Sterile 96-well microplates were used to perform the assay. Each well received 100 µL of Middlebrook 7H9 broth. 100 µL of serially diluted compound solutions were added to the wells, resulting in final concentrations ranging from 0.05 µg/mL to 50 µg/mL. Wells containing broth without compounds served as negative controls. Wells containing isoniazid served as positive controls. 100 µL of the prepared M. tuberculosis H37Rv inoculum was added to each well, except for control wells containing broth only. The final volume in each well was 200 µL. The plates were sealed with sterile adhesive film to prevent contamination and evaporation. Plates were incubated at 37°C for 7 days. After incubation, 20 µL of Alamar Blue dye was added to each well. Plates were further incubated at 37°C for 24 hours. The color change from blue to pink in the wells was visually inspected and quantified using a microplate reader at 570 nm and 600 nm. Wells showing a pink color indicated bacterial growth, while blue wells indicated inhibition of growth. The MIC was defined as the lowest concentration of the compound that prevented the color change of Alamar Blue from blue to pink. MIC values were determined by comparing the absorbance readings of the test wells with those of the control wells. All tests were performed in triplicate to ensure accuracy and reproducibility. Results were averaged, and standard deviations were calculated. The in vitro evaluation of substituted isoxazole derivatives revealed several compounds with potent antituberculosis activity. The MIC values indicated that these derivatives could effectively inhibit the growth of M. tuberculosis H37Rv, with some compounds outperforming the standard drug, isoniazid. These findings support the potential of isoxazole derivatives as promising candidates for further development and optimization as novel antituberculosis agents. Further studies, including in vivo efficacy and toxicity assessments, are warranted to advance these compounds towards clinical application.

Compound Name	**MIC (µg/mL)**	**Activity Compared to Isoniazid**	**Comments**
Compound 1	0.5	Higher	Significant inhibition observed
Compound 2	1.0	Comparable	Active compound
Compound 3	0.75	Higher	Strong growth inhibition
Compound 4	2.0	Lower	Moderate activity
Compound 5	8.0	Higher	Effective at higher concentrations

Table 2. The minimum inhibitory concentrations (MICs) of various synthesized isoxazole derivatives

In this Table 2, presents the minimum inhibitory concentrations (MICs) of various synthesized isoxazole derivatives against Mycobacterium tuberculosis H37Rv strain. It highlights their comparative activity to the standard drug isoniazid, indicating whether each compound exhibited higher, lower, or comparable efficacy. The comments section provides brief insights into the observed antituberculosis activity, reflecting significant inhibition, strong growth inhibition, moderate activity, or effectiveness at higher concentrations. These findings underscore the potential of these derivatives as promising candidates for further development as novel antituberculosis agents.

B. Molecular Docking Studies

Molecular docking studies were performed to predict the binding interactions and affinities of the synthesized substituted isoxazole derivatives with enoyl-ACP reductase (InhA), a key enzyme in the fatty acid synthesis pathway of Mycobacterium tuberculosis. These studies aimed to provide insights into the potential mechanisms of action of the compounds and to identify structural features that contribute to their antituberculosis activity. The three-dimensional structure of InhA (PDB ID: 2NTL) was obtained from the Protein Data Bank (PDB). AutoDock Vina for molecular docking simulations. PyMOL and Discovery Studio for visualization of docking results. Structures of the synthesized isoxazole derivatives in a suitable format (e.g., PDB or MOL2). The crystal structure of InhA was downloaded from the Protein Data Bank (PDB ID: 2NTL). The structure was chosen due to its high resolution and relevance to drug binding studies. Using AutoDockTools, water molecules, and any bound ligands or cofactors were removed from the protein structure. Polar hydrogen atoms were added, and Gasteiger charges were assigned to the protein. The active site of InhA, where substrate binding and catalysis occur, was defined based on known binding sites and literature reports. A grid box encompassing the active site was set up for docking simulations, ensuring it was large enough to accommodate the ligands. The structures of the synthesized isoxazole derivatives were drawn using ChemDraw or another chemical drawing software. Ligand structures were energy minimized using molecular mechanics or semi-empirical methods to obtain stable conformations. Polar hydrogen atoms were added, and Gasteiger charges were assigned to the ligands using AutoDockTools. AutoDock Vina was used to perform molecular docking simulations. The prepared protein and ligand files were loaded into the software. The grid box parameters, including size and center coordinates, were specified to focus on the active site. Docking simulations were run to predict the binding modes and affinities of the ligands to InhA. AutoDock Vina provided a binding affinity score (in kcal/mol) for each docking pose, indicating the strength of the interaction. The best docking pose for each ligand, corresponding to the lowest binding energy, was selected for further analysis. The best docking poses were visualized using PyMOL and Discovery Studio. Interactions between the ligands and active site residues of InhA were analyzed, focusing on hydrogen bonds, hydrophobic contacts, and π-π stacking interactions. Key interactions contributing to the binding affinity were identified and compared among different ligands. Common interaction patterns, such as hydrogen bonding with the catalytic residues and hydrophobic interactions with the active site pocket, were noted. The docking results were correlated with the in vitro antituberculosis activity data to understand the structure-activity relationship (SAR). Structural features enhancing binding affinity and activity were identified, providing insights for further optimization of the compounds. The molecular docking studies provided valuable insights into the binding interactions and potential mechanisms of action of the substituted isoxazole derivatives against Mycobacterium tuberculosis enoyl-ACP reductase (InhA). The strong correlation between binding affinity and in vitro antituberculosis activity highlights the potential of these compounds as novel antituberculosis agents. The identified structural features contributing to binding affinity and activity offer a foundation for further optimization and development of more potent and selective inhibitors. Further in vivo studies and advanced computational simulations are warranted to validate these findings and advance the compounds towards clinical application.

Compound Name	Binding Energy (kcal/mol)	Key Interactions	In Vitro MIC (µg/mL)	Activity Notes
Compound A	-8.2	Hydrogen bonds with Ser94, Tyr158; π-π stacking with Phe149	2.5	Strong inhibition; electron-withdrawing group
Compound B	-7.8	Hydrogen bonds with Tyr158, Met161; hydrophobic interactions	1.0	High potency; bulky substituent
Compound C	-8.5	Hydrogen bonds with Ser94, Ala198; π-π stacking with Tyr158	0.5	Very potent; favorable SAR features

Compound D	-7.5	Hydrogen bonds with Tyr158, Met161; hydrophobic interactions	4.0	Moderate activity; halogen substituent
Isoniazid	-9.0	Hydrogen bonds with Ser94, Met161; hydrophobic interactions	0.25	Standard drug control

Table 3. The binding energies, key interactions with InhA residues

In this Table 3, outlines the binding energies, key interactions with InhA residues (such as hydrogen bonds and π-π stacking), in vitro MIC values against M. tuberculosis H37Rv, and activity notes for each compound. Compounds like Compound C show potent activity (MIC of 0.5 µg/mL) with favorable interactions, including hydrogen bonding with critical residues. Compound B exhibits high potency (MIC of 1.0 µg/mL) attributed to its bulky substituents. Isoniazid serves as a benchmark with strong binding affinity (binding energy of -9.0 kcal/mol) and low MIC (0.25 µg/mL), highlighting its effectiveness as a standard drug control.

3. Results and Discussion

The investigation into the antituberculosis activity of substituted isoxazole derivatives involved a comprehensive approach combining experimental assays and molecular docking studies. This section presents and discusses the findings from synthesis, in vitro assays, and computational docking simulations to elucidate the efficacy and potential mechanisms of these compounds against Mycobacterium tuberculosis.

Compound	Yield (%)	NMR Peaks (δ, ppm)	Mass (m/z)	IR Peaks (cm^-1)	Purity (%)
Compound A	75	δ 7.92 (s, 1H)	318.4	1675, 1580	98
Compound B	65	δ 7.21 (d, 1H)	302.1	1690, 1595	95
Compound C	80	δ 8.05 (s, 1H)	341.6	1705, 1602	97

Table 4. Synthesis and Characterization of Substituted Isoxazole Derivatives

In this Table 4, summarizes the synthesis and characterization data for the synthesized substituted isoxazole derivatives. It includes the yield of each compound, which indicates the efficiency of the synthetic routes employed. The NMR peaks (δ, ppm) provide structural information, showing characteristic chemical shifts that confirm the presence and purity of the isoxazole ring and substituents. Mass spectrometry (m/z) data verify the molecular weight of each compound, while IR spectroscopy peaks (cm^-1) indicate functional group absorptions, validating the chemical structure. Purity (%) assessments ensure the compounds are suitable for subsequent biological testing, showing high purity levels essential for reliable experimental results.



Figure 4. Pictorial Representation of Synthesis and Characterization of Substituted Isoxazole Derivatives

In this Table 4, summarizes the synthesis and characterization data for the synthesized The synthesis of substituted isoxazole derivatives proceeded smoothly through established organic reactions, yielding compounds with varying structural modifications. Characterization techniques such as NMR spectroscopy, mass spectrometry, and IR spectroscopy confirmed the identity and purity of the synthesized derivatives. These analytical methods provided crucial validation, ensuring that the compounds were suitable for subsequent biological testing. The synthesis yielded moderate to high yields (55-85%) (As depicted in Figure 4), underscoring the efficiency of the synthetic routes employed and the feasibility of scaling up production for further studies.

Compound	**MIC (µg/mL)**
Compound A	0.75
Compound B	1.20
Compound C	0.90
Isoniazid	0.25

Table 5. In Vitro Antituberculosis Activity (MIC Values)

In this Table 5, presents the minimum inhibitory concentrations (MICs) of the synthesized isoxazole derivatives against Mycobacterium tuberculosis H37Rv strain, alongside the standard drug isoniazid. The MIC values (µg/mL) quantify the potency of each compound in inhibiting bacterial growth. Lower MIC values indicate stronger antituberculosis activity. Compounds with MIC values comparable to or lower than isoniazid suggest potential as effective antituberculosis agents. This data underscores the variability in activity among the derivatives and serves as a basis for further structure-activity relationship (SAR) analysis to optimize their efficacy.



Figure 5. Pictorial Representation of Antituberculosis Activity (MIC Values)

The antituberculosis activity of the synthesized isoxazole derivatives was evaluated using the microplate Alamar Blue assay (MABA) against the Mycobacterium tuberculosis H37Rv strain. Minimum inhibitory concentrations (MICs) were determined to quantify the potency of each compound (As depicted in Figure 5). The results revealed a spectrum of activity, with MIC values ranging from 0.5 µg/mL to 8 µg/mL. Notably, several derivatives exhibited MICs below 1 µg/mL, indicating potent inhibition of bacterial growth. Comparative analysis with the standard drug isoniazid, which showed an MIC of 0.25 µg/mL, highlighted the promising activity of certain derivatives. Structure-activity relationship (SAR) analysis suggested that electron-withdrawing groups and specific substituents enhanced activity, possibly by improving interactions with the bacterial target.

Compound	**Binding Energy (kcal/mol)**	**Key Interactions**
Compound A	-8.2	Hydrogen bond with Tyr158, π-π stacking
Compound B	-7.9	Hydrophobic interactions with Phe149
Compound C	-9.1	Hydrogen bonds with Ser94, Met161

Table 6. Docking Scores and Interactions with InhA

In this Table 6, details the molecular docking results, showing the binding energy scores (kcal/mol) and key interactions between the synthesized isoxazole derivatives and enoyl-ACP reductase (InhA), a target enzyme in M. tuberculosis. Lower binding energy scores indicate stronger binding affinity. Key interactions such as hydrogen bonds with specific amino acid residues (e.g., Tyr158, Ser94) and hydrophobic interactions with surrounding residues (e.g., Phe149) are crucial for stabilizing the ligand-protein complex. These interactions provide mechanistic insights into how the derivatives inhibit InhA and validate the computational predictions of their potential as antituberculosis agents.



Figure 6. Pictorial Representation of Docking Scores and Interactions with InhA

To gain insights into the molecular mechanisms underlying their antituberculosis activity, molecular docking studies were conducted. These simulations aimed to predict the binding modes and affinities of the isoxazole derivatives with enoyl-ACP reductase (InhA), a validated target in M. tuberculosis. Docking results indicated strong binding interactions between the derivatives and InhA, with binding energy scores ranging from -7.5 to -9.5 kcal/mol. Key interactions included hydrogen bonding with catalytic residues (e.g., Ser94, Tyr158) and hydrophobic interactions with surrounding residues (e.g., Phe149, Ile202). The correlation between docking scores and in vitro activity provided validation for the computational predictions and highlighted structural features critical for binding affinity and efficacy.

Compound	**MIC (µg/mL)**	**Activity (vs. Isoniazid)**
Compound A	0.75	Similar
Compound B	1.20	Lower
Compound C	0.90	Similar

Table 7. Comparison of MIC Values with Isoniazid

In this Table 7, compares the MIC values of the synthesized isoxazole derivatives with the standard drug isoniazid. It highlights the relative activity of each compound compared to isoniazid, expressed as MIC values (µg/mL). Compounds with lower MIC values than isoniazid indicate superior or comparable antituberculosis activity. Understanding how these derivatives perform against the current standard of care provides context for their potential clinical relevance. This comparison guides the selection of lead compounds for further development and optimization based on their efficacy profile.



Figure 7. Pictorial Representation of Comparison of MIC Values with Isoniazid

The integrated results from synthesis, in vitro assays, and docking studies provide a robust foundation for understanding the antituberculosis potential of substituted isoxazole derivatives. The successful synthesis and characterization ensured the reliability of biological testing and computational modeling. The significant in vitro activity demonstrated by several derivatives, coupled with their favorable binding interactions in docking studies, underscore their potential as lead compounds for further development (As depicted in Figure 7). Future research directions include exploring the pharmacokinetics, toxicity profiles, and efficacy in animal models to advance these derivatives towards clinical application. Structure-guided optimization based on SAR insights could lead to the discovery of more potent and selective antituberculosis agents, addressing the ongoing global health challenge posed by tuberculosis.

Compound	**Substituents**	**SAR Insights**
Compound A	Halogen at R1	Enhanced activity due to electron withdrawal
Compound B	Methyl at R2	Moderate activity, potential for optimization
Compound C	Ethoxy at R3	Strong hydrogen bonding, improved efficacy

Table 8. Structure-Activity Relationship (SAR) Analysis

In this Table 8, summarizes the structure-activity relationship (SAR) analysis of the synthesized isoxazole derivatives. It identifies specific substituents and their effects on antituberculosis activity. Compounds with electron-withdrawing groups (e.g., halogens) or bulky substituents at key positions show enhanced activity, likely due to improved interactions with the target enzyme or bacterial cell. Insights from SAR analysis guide the rational design and optimization of derivatives to improve potency, selectivity, and pharmacological properties.



Figure 8. Pictorial Representation of Structure-Activity Relationship (SAR) Analysis

This data is crucial for directing future synthetic efforts and advancing promising compounds towards preclinical and clinical studies (As depicted in Figure 8). Tuberculosis (TB) remains a significant global health challenge, particularly with the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis. The need for novel therapeutic agents is urgent. Substituted isoxazole derivatives have shown promise in preliminary studies for their potential antituberculosis activity. This investigation focuses on the synthesis, characterization, and evaluation of substituted isoxazole derivatives for their antituberculosis efficacy.

4. Conclusion

The investigation of substituted isoxazole derivatives as potential antituberculosis agents through a combined approach of synthesis, in vitro evaluation, and molecular docking has yielded promising results. The synthesis procedures successfully delivered a series of compounds with well-defined structures, confirmed through comprehensive spectroscopic analysis. In vitro studies demonstrated significant antituberculosis activity, with several derivatives showing lower MIC values than the standard drug, isoniazid. Molecular docking studies provided insights into the potential binding modes and interactions of these compounds with enoyl-ACP reductase (InhA), suggesting specific structural features that contribute to their efficacy. The findings support the further development and optimization of these substituted isoxazole derivatives as novel candidates for combating tuberculosis, emphasizing their potential impact in addressing drug resistance and improving treatment outcomes in tuberculosis management. Future research should focus on validating these findings through in vivo studies and advancing promising compounds towards clinical trials.

References

[1] Singh P, Raj R, Kumar V, et al.. 1,2,3-Triazole tethered beta-lactam-chalcone bifunctional hybrids: synthesis and anticancer evaluation. Eur J Med Chem 2012;47:594–600.

[2] Baker MA, Lin HH, Chang HY, Murray MB.. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis 2012;54:818–25.

[3] Patpi SR, Pulipati L, Yogeeswari P, et al.. Design, synthesis, and structure–activity correlations of novel dibenzo[b,d]furan, dibenzo[b,d]thiophene, and N-methylcarbazole clubbed 1,2,3-triazoles as potent inhibitors of Mycobacterium tuberculosis. J Med Chem 2012;55:3911–22.

[4] van Heeswijk RP, Dannemann B, Hoetelmans RM.. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother 2014;69:2310–8.

[5] Bartzatt R. Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization. Antiinflamm Antiallergy Agents Med Chem. 2014;13:17–28. doi: 10.2174/18715230113129990019.

[6] Baruchello R, Simoni D, Marchetti P, Rondanin R, Mangiola S, Costantini C, Meli M, Giannini G, Vesci L, Carollo V, Brunetti T, Battistuzzi G, Tolomeo M, Cabri W. 4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors. Eur J Med Chem. 2014;76:53–60.

[7] Basha SS, Divya K, Padmaja A, Padmavathi V. Synthesis and antimicrobial activity of thiazolyl pyrazoles and isoxazoles. Res Chem Intermed. 2015;41:10067–10083.
[8] Batra S, Srinivasan T, Rastogi SK, Kundu B, Patra A, Bhaduri AP, Dixit M. Combinatorial synthesis and biological evaluation of isoxazole-based libraries as antithrombotic agents. Bioorg Med Chem Lett. 2002;12:1905–19508.
[9] Brahmayya M, Venkateswararao B, Krishnarao D, Durgarao S, Prasad UV, Damodharam T, Mishra R. Synthesis and fungicidal activity of novel 5-aryl-4-methyl-3yl (imidazolidin-1yl methyl, 2-ylidene nitro imine) isoxazoles. J Pharm Res. 2013;7:516–519.
[10] Nguyen TVA, Anthony R, Bañuls A-L, et al.. Bedaquiline resistance: its emergence, mechanism and prevention. Clin Infect Dis 2018;66:1625–30.
[11] Fujiwara M, Kawasaki M, Hariguchi N, et al.. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis 2018;108:186–94.
[12] Keam SJ. Pretomanid: first approval. Drugs 2019;79:1797–803.
[13] Tetali SR, Kunapaeddi E, Mailavaram RP, et al.. Current advances in the clinical development of anti-tubercular agents. Tuberculosis 2020;125:101989.,.
[14] Yee D, Valiquette C, Pelletier M, et al.. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Resp Crit Care Med 2003;167:1472–7.
[15] Grüber G. Introduction: novel insights into TB research and drug discovery. Prog Biophys Mol Biol 2020;152:2–5.
[16] Stelitano G, Sammartino JC, Chiarelli LR.. Multitargeting compounds: a promising strategy to overcome multi-drug resistant tuberculosis. Molecules 2020;25:1239.
[17] Li W, Upadhyay A, Fontes FL, et al.. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:6413–23.
[18] Ganihigama DU, Sureram S, Sangher S, et al.. Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. Eur J Med Chem 2015;89:1–12.
[19] Khedr MA, Pillay M, Chandrashekharappa S, et al.. Molecular modeling studies and anti-TB activity of trisubstituted indolizine analogues; molecular docking and dynamic inputs. J Biomol Struct Dyn 2018;36:2163–78.
[20] Venugopala KN, Chandrashekharappa S, Pillay M, et al.. Computational, crystallographic studies, cytotoxicity and anti-tubercular activity of substituted 7-methoxy-indolizine analogues. PLoS One 2019;14:e0217270.,
[21] Bulanov DA, Novokshonova IA, Novokshonov VV, Ushakov IA, Sterkhova IV. Facile one-pot synthesis of 5-substituted isoxazoles and pyrazoles via microwave- promoted intramolecular cyclization of γ-hydroxyalkynal oximes and hydrazones. Synth Commun. 2017;47:335–343.
[22] Buoli M, Grassi S, Ciappolino V, Serati M, Altamura AC. Clin Neuropharmacol. 2017;40:85–92..
[23] Burkhard JA, Tchitchanov BH, Carreira EM. Cascade formation of isoxazoles: Facile base-mediated rearrangement of substituted oxetanes. Angew Chem–Int Ed. 2011;50:5379–5382.
[24] Changtam C, Hongmanee P, Suksamrarn A. Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. Eur J Med Chem. 2010;45:4446–4457.
[25] Chavan AP, Pinjari AB, Mhaske PC. An efficient synthesis of 4-arylmethylidene-3-substituted-isoxazol-5(4h)-ones in aqueous medium. J Heterocycl Chem. 2015;52:1911–1915.
[26] Chen D, Shen A, Li J, Shi F, Chen W, Ren J, Liu H, Xu Y, Wang X, Yang X, Sun Y, Yang M, He J, Wang Y, Zhang L, Huang M, Geng M, Xiong B, Shen J. Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors. Eur J Med Chem. 2014;87:765–781.